ALLIANCE PHARMA PLC

Share Issue/Capital Change • Dec 14, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0048J

Alliance Pharma PLC

14 December 2015

14 December 2015

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

ALLIANCE PHARMA PLC

Result of General Meeting

Alliance Pharma plc (AIM: APH) ("Alliance" or the "Company"), the specialty pharmaceutical company, is pleased to announce that, in connection with the proposed acquisition of the Healthcare Products Business from Sinclair IS Pharma plc (the "Acquisition") and the placing to part fund the Acquisition (the "Placing") announced by the Company on 26 November 2015, all resolutions put to shareholders at the General Meeting today were duly passed.

Completion of the Acquisition and Placing ("Completion") and re-admission of the Company's enlarged issued share capital to trading on AIM ("Re-Admission") are expected to take place at 8.00am on 17 December 2015. Following Completion and Re-admission the Company's issued ordinary share capital will be 468,179,146 ordinary shares.

Issued share capital at Re-Admission

The Company's enlarged issued share capital of 468,179,146 shares includes an existing issued share capital of 264,520,611 ordinary shares and not 264,520,610 shares as had been incorrectly stated in the Company's RNS announcement and Admission Document relating to the Acquisition and Placing, dated 26 November 2015.

A reconciliation of the Company's current issued share capital to the number of shares that the Company has admitted to trading, demonstrated that a total of 1,269,296 shares have been issued and allotted by the Company historically but have not been admitted to trading on AIM, as a result of an administrative oversight. Consequently, an application has been made for these 1,269,296 shares, which are included in the Company's existing issued share capital figure of 264,520,611, to be admitted to trading on AIM. Admission of these 1,269,296 shares is expected to take place at 8.00am on 17 December 2015, such that the enlarged issued share capital of the Company at completion will be 468,179,146 ordinary shares, as stated above.

The above figure of 468,179,146 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Further information:

Alliance Pharma plc				+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Numis Securities Limited				+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield /  Hugo Rubinstein
Corporate Broking: David Poutney / James Black
Buchanan				+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMLLFEEFLLSLIE